Alexion’s newly approved rare-disease drug notches another clinical trial win

Alexion Pharmaceuticals (ALXN) said Monday that its newly approved drug Ultomiris achieved the primary goal of a late-stage clinical trial involving patients with a rare type of kidney disease.